ONCOblot ®, a blood test for cancer has been tested in a clinical trial to detect malignant mesothelioma, with very promising results.
The ONCOblot ® blood test has been designed to detect ENOX2, a protein that is only found on the surface of cancer cells. The ENOX2 proteins are released into the blood stream, where they can be detected.
In addition to finding these proteins in the blood stream, thereby detecting the presence of cancer, the test can also determine the specific location of the cancer. This is possible because the ENOX2 proteins are slightly different depending on which body tissue it has come from. By measuring the molecular weight and isoelectric point (the pH at which a particular molecule carries no net electrical charge) of the ENOX2, it is possible to pinpoint which tissue the ENOX2 came from, and therefore the location of the cancer.
The ONCOblot ® test recently underwent clinical testing in a trial of early detection of malignant mesothelioma. The study results found that this test was able to detect the presence of the tumor marker 4-10 years earlier than symptoms would start to appear. The test has been shown to be effective at detecting early stage cancers (Stage 0) that are smaller than 2mm in size. Early detection is key in cancer treatment, especially in aggressive tumors such as malignant mesothelioma.
Due to the success of the new test in detecting malignant mesothelioma, the company is planning larger-scale clinical trials aimed at investigating the use of ENOX2 as a biomarker for detecting other types of cancer.
News Release : The test that reveals cancer sooner http://www.eurekalert.org/pub_releases/2016-02/ol-ttt020316.php Last Accessed: February 4, 2016.
ONCOblot website: http://oncoblotlabs.com/